CATH Search:   
       by CATH code, keyword
QuickSearch:   
by PDB,NDB,UniProt,PROSITE Code or Search Term(s)  
(use 'Shift Left-Click' to collapse/expand all levels downwards; use 'Control Left-Click' to collapse/expand all levels upwards)
 
(-)
Class: Mainly Beta (13760)
(-)
Architecture: Beta Barrel (4804)
(-)
Topology: Cathepsin D, subunit A; domain 1 (745)
(-)
Homologous Superfamily: Acid Proteases (745)
(-)
Human (Homo sapiens) (161)
1AVFA:172-327; J:172-328; A:2-171; J:2-171ACTIVATION INTERMEDIATE 2 OF HUMAN GASTRICSIN FROM HUMAN STOMACH
1BBSA:171-325; A:1-170X-RAY ANALYSES OF PEPTIDE INHIBITOR COMPLEXES DEFINE THE STRUCTURAL BASIS OF SPECIFICITY FOR HUMAN AND MOUSE RENINS
1BILA:171-325; B:171-325; B:1-170; A:1-170CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
1BIMA:171-325; B:171-325; B:1-170; A:1-170CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
1FKNA:14-146; B:14-146; A:147-385; B:147-385STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
1FLHA:171-325; A:1-170CRYSTAL STRUCTURE OF HUMAN UROPEPSIN AT 2.45 A RESOLUTION
1HRNA:171-325; B:171-325; B:1-170; A:1-170HIGH RESOLUTION CRYSTAL STRUCTURES OF RECOMBINANT HUMAN RENIN IN COMPLEX WITH POLYHYDROXYMONOAMIDE INHIBITORS
1HTRB:172-328; B:1-171CRYSTAL AND MOLECULAR STRUCTURES OF HUMAN PROGASTRICSIN AT 1.62 ANGSTROMS RESOLUTION
1LYAA:1-97; C:1-97; B:106-346; D:106-346CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
1LYBA:1-97; C:1-97; B:106-346; D:106-346CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
1LYWA:3-97; C:3-97; E:3-97; G:3-97; B:106-346; D:106-346; F:106-346; H:106-346CATHEPSIN D AT PH 7.5
1M4HA:14-146; A:147-385; B:147-385; B:14-146CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR OM00-3
1PSNA:171-325; A:1-170THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN
1PSOE:171-325; E:1-170THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN
1Q9PA:1-95SOLUTION STRUCTURE OF THE MATURE HIV-1 PROTEASE MONOMER
1QRPE:171-325; E:1-170HUMAN PEPSIN 3A IN COMPLEX WITH A PHOSPHONATE INHIBITOR IVA-VAL-VAL-LEU(P)-(O)PHE-ALA-ALA-OME
1RNEA:171-325; A:1-170THE CRYSTAL STRUCTURE OF RECOMBINANT GLYCOSYLATED HUMAN RENIN ALONE AND IN COMPLEX WITH A TRANSITION STATE ANALOG INHIBITOR
1SGZA:14-146; A:147-385; B:147-385; C:147-385; D:147-385; B:14-146; C:14-146; D:14-146CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTIC DOMAIN.
1TQFA:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
1W50A:14-146; A:147-385APO STRUCTURE OF BACE (BETA SECRETASE)
1W51A:14-146; A:147-385BACE (BETA SECRETASE) IN COMPLEX WITH A NANOMOLAR NON-PEPTIDIC INHIBITOR
1XN2A:14-146; B:14-146; A:147-385; B:147-385; C:147-385; D:147-385; C:14-146; D:14-146NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE.
1XN3A:14-146; A:147-385; B:147-385; C:147-385; D:147-385; B:14-146; C:14-146; D:14-146CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONG INHIBITOR WITH ADDITIONAL UPSTREAM RESIDUES.
1XS7D:14-146; D:147-385CRYSTAL STRUCTURE OF A CYCLOAMIDE-URETHANE-DERIVED NOVEL INHIBITOR BOUND TO HUMAN BRAIN MEMAPSIN 2 (BETA-SECRETASE).
1YM2A:14-146; A:147-385; C:147-385; B:147-385; B:14-146; C:14-146CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AUR200
1YM4A:14-146; B:14-146; C:14-146; B:147-385; A:147-385; C:147-385CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AMK640
2B8LA:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
2B8VA:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH L-L000430,469
2EWYA:30-162; B:30-162; C:30-162; D:30-162; A:163-398; B:163-398; C:163-398; D:163-398CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR
2F3EA:14-146; A:147-385; B:147-385; C:147-385; B:14-146; C:14-146CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH AXQ093, A MACROCYCLIC INHIBITOR
2F3FA:14-146; B:14-146; C:14-146; A:147-385; B:147-385; C:147-385CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH BDF488, A MACROCYCLIC INHIBITOR
2FDPA:14-146; B:14-146; C:14-146; B:147-385; A:147-385; C:147-385CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH AN AMINO-ETHYLENE INHIBITOR
2FS4A:175-332; B:175-332; A:3-174; B:3-174KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
2G1NA:177-334; B:177-334; A:3-176; B:3-176KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING
2G1OA:177-334; B:177-334; A:3-176; B:3-176KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING
2G1RA:177-334; B:177-334; A:3-176; B:3-176KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
2G1SA:177-334; B:177-334; A:3-176; B:3-176KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
2G1YA:177-334; B:177-334; A:3-176; B:3-176KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING
2G20A:177-334; B:177-334; A:3-176; B:3-176KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
2G21A:175-332; B:175-332; A:3-174; B:3-174KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING
2G22A:177-334; B:177-334; A:3-176; B:3-176KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING
2G24A:175-332; B:175-332; A:3-174; B:3-174KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING
2G26A:175-332; B:175-332; A:3-174; B:3-174KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING
2G27A:175-332; B:175-332; A:3-174; B:3-174KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING
2G94A:14-146; B:14-146; C:14-146; D:14-146; A:147-385; B:147-385; C:147-385; D:147-385CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A POTENT AND HIGHLY SELECTIVE INHIBITOR.
2HIZA:14-146; B:14-146; C:14-146; A:147-385; B:147-386; C:147-386CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR
2HM1A:14-146; A:147-386CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR (2)
2I4QA:177-335; B:177-335; A:0-176; B:0-176HUMAN RENIN/PF02342674 COMPLEX
2IQGA:14-146; A:147-386CRYSTAL STRUCTURE OF HYDROXYETHYL SECONDARY AMINE-BASED PEPTIDOMIMETIC INHIBITOR OF HUMAN BETA-SECRETASE (BACE)
2IRZA:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH INHIBITOR
2IS0A:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH INHIBITOR
2NTRA:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO INHIBITOR
2OAHA:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
2OF0A:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 5
2OHKA:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 1-AMINO-ISOQUINOLINE
2OHLA:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 2-AMINOQUINOLINE
2OHMA:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH N~3~-BENZYLPYRIDINE-2,3-DIAMINE
2OHNA:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 4-(4-FLUOROBENZYL)PIPERIDINE
2OHPA:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 3
2OHQA:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 4
2OHRA:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 6A
2OHSA:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 6B
2OHTA:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 7
2OHUA:14-146; A:147-385X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8B
2P4JA:14-146; B:14-146; C:14-146; D:14-146; A:147-385; B:147-385; C:147-385; D:147-385CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3
2P83A:14-146; B:14-146; C:14-146; A:147-385; B:147-386; C:147-386POTENT AND SELECTIVE ISOPHTHALAMIDE S2 HYDROXYETHYLAMINE INHIBITOR OF BACE1
2P8HA:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
2PH6A:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
2PH8A:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
2Q11A:14-146; B:14-146; C:14-146; A:147-385; B:147-385; C:147-385STRUCTURE OF BACE COMPLEXED TO COMPOUND 1
2Q15A:14-146; A:147-385STRUCTURE OF BACE COMPLEXED TO COMPOUND 3A
2QK5A:75-207; B:208-446; A:208-447; B:75-207STRUCTURE OF BACE1 BOUND TO SCH626485
2QMDA:75-207; B:208-446; A:208-447; B:75-207STRUCTURE OF BACE BOUND TO SCH722924
2QMFA:75-207; B:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH735310
2QMGA:75-207; B:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH745966
2QP8A:75-207; B:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH734723
2QU2A:76-208; A:209-445BACE1 WITH COMPOUND 1
2QU3A:76-208; A:209-445BACE1 WITH COMPOUND 2
2QZKA:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH I21
2QZLA:14-146; A:147-385CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH IXS
2RENA:182-337; A:7-181STRUCTURE OF RECOMBINANT HUMAN RENIN, A TARGET FOR CARDIOVASCULAR-ACTIVE DRUGS, AT 2.5 ANGSTROMS RESOLUTION
2VA5A:14-146; A:147-386X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8C
2VA7A:14-146; A:147-386X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 27
2VIEA:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-1-BENZYL-2-HYDROXY-3-((1,1,5-TRIMETHYLHEXYL)AMINO)PROPYL)-3-(ETHYLAMINO)-5-(2-OXOPYRROLIDIN-1-YL)BENZAMIDE
2VIJA:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH 3-(1,1-DIOXIDOTETRAHYDRO-2H-1, 2-THIAZIN-2-YL)-5-(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-1-( PHENYLMETHYL)-3-(1,2,3,4-TETRAHYDRO-1-NAPHTHALENYLAMINO) PROPYL)BENZAMIDE
2VIYA:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(PENTYLSULFONYL)BENZAMIDE
2VIZA:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(2-OXO-1-PYRROLIDINYL)-5-(PROPYLOXY) BENZAMIDE
2VJ6A:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE
2VJ7A:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH 3-(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-1-(PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL) METHYL)AMINO)PROPYL)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE
2VJ9A:75-207; A:208-451HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(CYCLOHEXYLAMINO)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE
2VKMA:14-146; A:147-385; B:147-385; C:147-385; D:147-385; B:14-146; C:14-146; D:14-146CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE)
2VNMA:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH 3-(1,1-DIOXIDOTETRAHYDRO-2H-1, 2-THIAZIN-2-YL)-5-(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-1-( PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)BENZAMIDE
2VNNA:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S,2R)-2-HYDROXY-1-(PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)-1-METHYL-3,4-DIHYDRO-1H-(1,2,5)THIADIAZEPINO(3,4,5-HI)INDOLE-9-CARBOXAMIDE 2,2-DIOXIDE
2WEZA:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH 1-ETHYL-N-((1S,2R)-2-HYDROXY-3-(((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-4-(2-OXO-1-PYRROLIDINYL)-1H-INDOLE-6-CARBOXAMIDE
2WF0A:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH 4-ETHYL-N-((1S,2R)-2-HYDROXY-1-(PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)-8-(2-OXO-1-PYRROLIDINYL)-6-QUINOLINECARBOXAMIDE
2WF1A:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S,2R)-2-HYDROXY-3-(((3-(METHYLOXY)PHENYL(METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-1-METHYL-3,4-DIHYDRO-1H-(1,2,5)THIADIAZEPINO(3,4,5-HI)INDOLE-9-CARBOXAMIDE 2,2-DIOXIDE
2WF2A:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH 8-ETHYL-N-((1S,2R)-2-HYDROXY-3-(((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-1-METHYL-3,4,7,8-TETRAHYDRO-1H,6H-(1,2,5) THIADIAZEPINO(5,4,3-DE)QUINOXALINE-10-CARBOXAMIDE 2,2-DIOXIDE
2WF3A:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH 6-(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-3-(((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL)PROPYL)-1-METHYL-1, 3,4,5-TETRAHYDRO-2,1-BENZOTHIAZEPINE-8-CARBOXAMIDE 2,2-DIOXIDE
2WF4A:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH 6-ETHYL-1-METHYL-N-((1S)-2-OXO-1-(PHENYLMETHYL)-3-(TETRAHYDRO-2H-PYRAN-4-YLAMINO)PROPYL)-1,3,4,6-TETRAHYDRO(1,2)THIAZEPINO(5,4,3-CD)INDOLE-8-CARBOXAMIDE 2,2-DIOXIDE
2WJOA:14-146; A:147-388HUMAN BACE (BETA SECRETASE) IN COMPLEX WITH CYCLOHEXANECARBOXYLIC ACID (2-(2-AM INO-6-PHENOXY-4H-QUINAZOLIN-3-YL)-2-CYCLOHEXYL-ETHYL)-AMIDE
2XFIA:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-((METHYLSULFONYL)(PHENYL)AMINO) BENZAMIDE
2XFJA:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE
2XFKA:75-207; A:208-447HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-((METHYLSULFONYL)( PHENYL)AMINO)BENZAMIDE
2ZDZA:76-208; A:209-446X-RAY STRUCTURE OF BACE-1 IN COMPLEX WITH COMPOUND 3.B.10
2ZE1A:76-208; A:209-446X-RAY STRUCTURE OF BACE-1 IN COMPLEX WITH COMPOUND 6G
2ZHRA:14-146; B:14-146; B:147-385; A:147-385CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH OM99-2 AT PH 5.0
2ZHSA:14-146; A:147-385CRYSTAL STRUCTURE OF BACE1 AT PH 4.0
2ZHTA:14-146; A:147-385CRYSTAL STRUCTURE OF BACE1 AT PH 4.5
2ZHUA:14-146; A:147-385CRYSTAL STRUCTURE OF BACE1 AT PH 5.0
2ZHVA:14-146; A:147-385CRYSTAL STRUCTURE OF BACE1 AT PH 7.0
2ZJHA:14-146; A:147-385CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-(1-BENZYL-PIPERIDIN-4-YL)-4-MERCAPTO-BUTYRAMIDE
2ZJIA:14-146; A:147-385CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(2,6-DIMETHOXY-BENZYL)-PIPERIDIN-4-YL]-4-MERCAPTO-BUTYRAMIDE
2ZJJA:14-146; A:147-385CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID (2-MERCAPTO-ETHYL)-AMIDE
2ZJKA:14-146; B:14-146; C:14-146; B:147-385; A:147-385; C:147-385CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID(3-MERCAPTO-PROPYL)-AMIDE
2ZJLA:14-146; A:147-385CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-BROMO-2,3-DIMETHOXY-BENZYL)-PIPERIDIN-4-YL]-4-MERCAPTO-BUTYRAMIDE
2ZJMA:14-146; A:147-385CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-CHLORO-2-ISOPROPOXY-3-METHOXY-BENZYL)-PIPERIDIN-4-YL]-2-(4-SULFAMOYL-PHENOXY)-ACETAMIDE
2ZJNA:14-146; A:147-385CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-CHLORO-2-ISOPROPOXY-3-METHOXY-BENZYL)-PIPERIDIN-4-YL]-2-(2-METHYL-4-SULFAMOYL-PHENOXY)-ACETAMIDE
3BRAA:14-146; A:147-386BACE-1 COMPLEXED WITH COMPOUND 1
3BUFA:14-146; A:147-386BACE-1 COMPLEXED WITH COMPOUND 2
3BUGA:14-146; A:147-386BACE-1 COMPLEXED WITH COMPOUND 3
3BUHA:14-146; A:147-386BACE-1 COMPLEXED WITH COMPOUND 4
3CIBA:75-207; B:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH727596
3CICA:75-207; B:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH709583
3CIDA:75-207; B:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH726222
3CKPA:14-146; B:14-146; C:14-146; C:147-386; A:147-386; B:147-386CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
3CKRA:14-146; B:14-146; C:14-146; C:147-386; A:147-386; B:147-386CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
3DM6A:14-146; B:14-146; C:14-146; C:147-385; B:147-385; A:147-385BETA-SECRETASE 1 COMPLEXED WITH STATINE-BASED INHIBITOR
3EXOA:14-146; A:147-385CRYSTAL STRUCTURE OF BACE1 BOUND TO INHIBITOR
3FKTA:34-166; A:167-403CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH SPIROPIPERDINE IMINOHYDANTOIN INHIBITOR
3GW5A:182-339; B:182-339; B:7-181; A:7-181CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH A NOVEL INHIBITOR
3H0BA:14-146; B:14-146; C:14-146; A:147-385; B:147-385; C:147-385DISCOVERY OF AMINOHETEROCYCLES AS A NOVEL BETA-SECRETASE INHIBITOR CLASS
3HVGA:14-146; B:14-146; C:14-146; B:147-385; C:147-385; A:147-385STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH EV0
3HW1A:14-146; C:14-146; B:14-146; A:147-385; B:147-385; C:147-385STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH LIGAND EV2
3I25A:14-146; A:147-385; B:147-385; C:147-385; B:14-146; C:14-146POTENT BETA-SECRETASE 1 HYDROXYETHYLENE INHIBITOR
3IGBA:76-208; A:209-447BACE-1 WITH COMPOUND 3
3IN3A:76-208; A:209-446BACE1 WITH COMPOUND 30
3IN4A:76-208; A:209-446BACE1 WITH COMPOUND 38
3INDA:76-208; A:209-448BACE1 WITH THE AMINOHYDANTOIN COMPOUND 29
3INEA:76-208; A:209-447BACE1 WITH THE AMINOHYDANTOIN COMPOUND S-34
3INFA:76-208; A:209-448BACE1 WITH THE AMINOHYDANTOIN COMPOUND 37
3INHA:76-208; A:209-448BACE1 WITH THE AMINOHYDANTOIN COMPOUND R-58
3IVHA:75-207; A:208-447DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS
3IVIA:75-207; C:208-447; B:208-447; A:208-447; B:75-207; C:75-207DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS
3IXJA:62-194; C:195-433; A:195-433; B:195-433; B:62-194; C:62-194CRYSTAL STRUCTURE OF BETA-SECRETASE 1 IN COMPLEX WITH SELECTIVE BETA-SECRETASE 1 INHIBITOR
3K5CA:14-146; A:147-385; B:147-385; C:147-385; B:14-146; C:14-146HUMAN BACE-1 COMPLEX WITH NB-216
3K5DA:14-146; B:14-146; C:14-146; A:147-385; B:147-385; C:147-386CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH AHM178
3K5FA:14-146; B:14-146; C:14-146; A:147-385; B:147-385; C:147-385HUMAN BACE-1 COMPLEX WITH AYH011
3K5GA:14-146; A:147-385; B:147-385; C:147-385; B:14-146; C:14-146HUMAN BACE-1 COMPLEX WITH BJC060
3KM4A:182-339; B:182-339; B:7-181; A:7-181OPTIMIZATION OF ORALLY BIOAVAILABLE ALKYL AMINE RENIN INHIBITORS
3KMXA:75-207; B:208-446; A:208-447; B:75-207STRUCTURE OF BACE BOUND TO SCH346572
3KMYA:75-207; B:208-446; A:208-447; B:75-207STRUCTURE OF BACE BOUND TO SCH12472
3KN0B:75-207; B:208-446; A:208-447; A:75-207STRUCTURE OF BACE BOUND TO SCH708236
3L38A:76-208; A:209-445BACE1 IN COMPLEX WITH THE AMINOPYRIDINE COMPOUND 44
3L3AA:76-208; A:209-446BACE-1 WITH THE AMINOPYRIDINE COMPOUND 32
3L58A:75-207; B:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH589432
3L59A:75-207; B:208-446; A:208-447; B:75-207STRUCTURE OF BACE BOUND TO SCH710413
3L5BA:75-207; B:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH713601
3L5CB:75-207; A:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH723871
3L5DB:75-207; A:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH723873
3L5EA:75-207; B:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH736062
3L5FA:75-207; B:75-207; B:208-446; A:208-447STRUCTURE OF BACE BOUND TO SCH736201